Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

CG Oncology

Ownership
Private
Modalities
Oncolytic immunotherapyViral therapy

CG Oncology General Information

Cretostimogene grenadenorepvec (CG0070) has shown a 75% complete response rate in the Phase 3 BOND-003 trial for BCG-unresponsive high-risk NMIBC, with durable responses in many patients and a favorable safety profile (common side effects: bladder spasms, dysuria, hematuria).

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Irvine, California
United States

Drug Pipeline

No pipeline data available

For full access to CG Oncology's pipeline data

Book a demo

Key Partnerships

Merck (pembrolizumab combination)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

CG Oncology Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view CG Oncology's complete valuation and funding history, request access »

CG Oncology Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals